Trial Profile
A Pilot Study of Dacomitinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 07 Jun 2019
Price :
$35
*
At a glance
- Drugs Dacomitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Apr 2019 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
- 24 Apr 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2020.
- 04 Dec 2018 New trial record